Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M Davis

Showing results (1-10 of 504) with videos related to

Pageof 51
Sort By:
Dental Historian : Lindsay Club Newsletter|July 24, 2013
The United Kingdom dental tradeJohn M Davis
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 3, 2019
Commentary on: Corponi F., Fabbri C, Bitter, I. Montgomery, S., Vieta, E., Kaspar, S., Pallanti S., Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperoneJohn M Davis
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2016
Editorial: The Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis: Is It a Valid Measure of Disease Activity?John M Davis
The Journal of Clinical Psychiatry|June 2, 2016
The incidence of seizures with antipsychoticsJohn M Davis
The Journal of Rheumatology|June 15, 2022
The Patient Experience of Drug Side Effects in Rheumatoid Arthritis: Intriguing Data From an Exploratory Online SurveyJohn M Davis
Idrugs : the Investigational Drugs Journal|February 8, 2005
American College of Neuropsychopharmacology--43rd annual meeting. 12-16 December 2004, San Juan, Puerto RicoJohn M Davis
Clinical Therapeutics|June 15, 2019
Rheumatoid Arthritis: A Severe Disease That Preventive Approaches Would Greatly BenefitJohn M Davis
The New England Journal of Medicine|February 3, 2006
The choice of drugs for schizophreniaJohn M Davis
The American Journal of Psychiatry|February 4, 2010
The use of depot medications in the treatment of schizophreniaJohn M Davis
The Journal of Rheumatology|September 3, 2015
Toward Quality of Cardiovascular Preventive Care for Patients with Rheumatic DiseasesJohn M Davis
Pageof 51

Showing results (1-10 of 504) with videos related to

Sort By:
Pageof 51
Dental Historian : Lindsay Club Newsletter|July 24, 2013
The United Kingdom dental tradeJohn M Davis
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 3, 2019
Commentary on: Corponi F., Fabbri C, Bitter, I. Montgomery, S., Vieta, E., Kaspar, S., Pallanti S., Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperoneJohn M Davis
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2016
Editorial: The Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis: Is It a Valid Measure of Disease Activity?John M Davis
The Journal of Clinical Psychiatry|June 2, 2016
The incidence of seizures with antipsychoticsJohn M Davis
The Journal of Rheumatology|June 15, 2022
The Patient Experience of Drug Side Effects in Rheumatoid Arthritis: Intriguing Data From an Exploratory Online SurveyJohn M Davis
Idrugs : the Investigational Drugs Journal|February 8, 2005
American College of Neuropsychopharmacology--43rd annual meeting. 12-16 December 2004, San Juan, Puerto RicoJohn M Davis
Clinical Therapeutics|June 15, 2019
Rheumatoid Arthritis: A Severe Disease That Preventive Approaches Would Greatly BenefitJohn M Davis
The New England Journal of Medicine|February 3, 2006
The choice of drugs for schizophreniaJohn M Davis
The American Journal of Psychiatry|February 4, 2010
The use of depot medications in the treatment of schizophreniaJohn M Davis
The Journal of Rheumatology|September 3, 2015
Toward Quality of Cardiovascular Preventive Care for Patients with Rheumatic DiseasesJohn M Davis
Pageof 51